Diagnostic value of measuring pancreatic isoamylase with a double-monoclonal antibody immunoassay in serum of hospitalized hyperamylasemic patients.
We evaluated the diagnostic utility of measuring pancreatic isoamylase (P-AMY) with a double-monoclonal antibody technique in a population of 43 consecutive hospitalized hyperamylasemic patients in comparison with serum pancreatic lipase (LPS) activity. In 27 cases (62.8%), the final diagnosis was acute pancreatitis. Predictive values were calculated for P-AMY and LPS activities, and a P-AMY percentage was calculated for selected decision levels. The maximal diagnostic efficiency was 0.930, 0.814, and 0.767 for LPS, P-AMY activity, and P-AMY percentage, respectively, indicating that serum LPS measurement was clinically superior to P-AMY for distinguishing patients with or without pancreatitis. Measurement of both P-AMY activity and percentage in serum did not significantly improve diagnostic accuracy.
Panteghini
M
M
First Laboratory of Clinical Pathology, Spedali Civili, Brescia, Italy.
Pagani
F
F
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007517:Isoamylase / Q000097:blood*; D008049:Lipase / Q000097:blood; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000201:enzymology*; D010195:Pancreatitis / Q000175:diagnosis* / Q000201:enzymology
D000911:Antibodies, Monoclonal; D008049:Lipase; D007517:Isoamylase